Table 2
Author, ref | (year) | n pIMRT (dIMRT) | HNC subsites | T3/4, rec, OCC | pIMRT dose | Chemotherapy | 2-y L(R)C | median FU |
|---|---|---|---|---|---|---|---|---|
Lee et al [15] | (2003) | 43 (107) | all | 53, 0, 2% | 66 Gy | 35% of pIMRT | 83% LC | 25 (6–78) |
Chao et al [9] | (2004) | 74 (52) | all | 52, 0, 12% | ~68 Gy (+/-4.7) | none of pIMRT | 90% LRC | 26 (12–55) |
Feng et al [10] | (2005) | 86 (72) | all but NPC/SNC | 90 lll/lV, 3, 23% | ~70 Gy (66–76) | 12% of all | ~85% LRC | 36 (6–127) |
Yao et al [12] | (2005) | 51 (100) | all | 53, 0, 19% | 64–66 Gy | none of pIMRT | ~92% LC | 18 (2–60) |
own | (2006) | 71 (230) | all SCC | 25, 18, 31% | ~66 Gy (60–70) | 83% of pIMRT | 95% LC | 17.6 (2–48) |
91% NC |